380550 — Neurophet Income Statement
0.000.00%
Last trade - 00:00- KR₩246bn
- KR₩247bn
- KR₩2bn
Annual income statement for Neurophet, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 697 | 1,562 | 2,216 |
| Cost of Revenue | |||
| Gross Profit | — | -4,928 | -6,833 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 9,333 | 13,326 | 16,865 |
| Operating Profit | -8,636 | -11,764 | -14,649 |
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -8,449 | 5,263 | -15,101 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -8,449 | 5,263 | -15,101 |
| Net Income Before Extraordinary Items | |||
| Net Income | -8,449 | 5,263 | -15,101 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -8,449 | 5,263 | -15,101 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -736 | 459 | -1,316 |
| Dividends per Share |